Cencora delivered a strong start to fiscal 2026 with Q1 adjusted diluted EPS of $4.08, up 9% year-over-year, on revenue of $85.9 billion, which increased 5.5%. The company raised its full-year fiscal 2026 guidance for adjusted operating income growth to 11.5%–13.5% and revenue growth to 7%–9%, driven by the completion of the majority acquisition of OneOncology and robust performance in the US Healthcare Solutions segment. US segment operating income grew 21% to $831 million, fueled by specialty strength and the Retina Consultants of America (RCA) acquisition, while International segment operating income declined 14% due to timing issues in a developing market. Management paused share repurchases to prioritize debt paydown following the OneOncology deal, yet reaffirmed its full-year EPS guidance range of $17.45 to $17.75.
| Metric | Value | Change |
|---|---|---|
| Q1 Adjusted Diluted EPS | $4.08 | +9% year-over-year |
| Q1 Consolidated Revenue | $85.9 billion | +5.5% year-over-year |
| Q1 US Healthcare Solutions Operating Income | $831 million | +21% year-over-year |
| Q1 Consolidated Operating Income | $1.1 billion | +12% year-over-year |
| Q1 Gross Profit Margin | 3.48% | +37 basis points year-over-year |
| Q1 GLP-1 Sales Growth | +$1 billion | +11% year-over-year |
| Fiscal 2026 Revenue Growth Guidance | 7% to 9% | Raised from 5% to 7% |
| Fiscal 2026 Operating Income Growth Guidance | 11.5% to 13.5% | Raised from 8% to 10% |
Cencora is aggressively executing an 'MSO-first' strategy to deepen its presence in high-growth specialty markets like oncology and retina. By acquiring a 92% stake in OneOncology and fully owning Retina Consultants of America (RCA), Cencora moves beyond simple distribution into managing practice operations, revenue cycle, and clinical trials. This creates a sticky, higher-margin ecosystem that aligns the interests of physicians, patients, and pharmaceutical manufacturers.
The company is leveraging its scale to navigate complex regulatory and pricing environments. Management highlighted success in maintaining gross profit dollars despite the Inflation Reduction Act (IRA) price negotiations and list price changes, citing strong relationships with manufacturers. This pricing power reinforces their defensive moat as a distributor.
Strategic capital allocation is shifting toward M&A and debt reduction. The decision to pause share repurchases to fund the OneOncology acquisition and pay down debt signals a focus on long-term value creation over short-term EPS engineering. Management noted that while divestitures in the 'Other' segment (like MWI) could cause short-term dilution, they are necessary to refocus the portfolio on high-growth healthcare solutions.
There is a significant focus on cross-pollinating capabilities across the MSO platform. Management identified clinical trial excellence (from RCA) and revenue cycle management as key 'accelerators' that can be deployed across OneOncology's vast network. This suggests that future growth will come not just from volume, but from selling high-value services to the providers they supply.
Interest expense is set to surge significantly in the coming quarters. Management warned that Q2 net interest expense will be approximately double the Q1 figure of $72 million due to debt taken on for the OneOncology acquisition and seasonal working capital needs. Full-year interest expense guidance was raised by ~$165 million, which will pressure net income margins.
The International Healthcare Solutions segment faced a notable operational stumble, with operating income down 14% (17% constant currency). While management attributes this to a 'timing difference' for manufacturer price adjustments in a developing market, such specific volatility in emerging markets remains a risk factor for the segment's consistency.
The core US business faces tough comparisons and customer losses. Management cited the loss of a large grocery customer and an oncology customer acquired by a competitor as headwinds. While they are offsetting this with new growth, the reliance on specific customer wins (like health systems) to fill these gaps introduces execution risk.
The pause in share repurchases removes a key lever for EPS growth. With the diluted share count expected to be roughly flat (105.5 million shares) rather than declining, EPS growth must be driven entirely by operational improvements and M&A accretion, leaving less room for error.
Overall: Management exhibited a high level of confidence and enthusiasm regarding the company's strategic direction, particularly the expansion of the MSO platform with OneOncology. They were direct and detailed in their responses to analyst questions about accounting mechanics and segment performance, maintaining a positive outlook despite near-term headwinds like interest expense and international timing issues.
Confidence: HIGH - Management raised guidance immediately following a major acquisition and spoke with certainty about the 'neutral to EPS' target for OneOncology. They provided specific numbers to defend their core business performance against concerns of deceleration.
Reaffirmed range of $17.45 to $17.75. This reflects strong execution in the US segment and the expected contribution from OneOncology, offset by the pause in share repurchases and higher interest costs.
Raised to 7% to 9% (previously 5% to 7%). This includes the contribution from OneOncology and solid utilization trends, partially offset by the loss of a large grocery customer and an oncology customer.
Raised to 11.5% to 13.5% (previously 8% to 10%). The increase is driven by the OneOncology acquisition and continued strength in the US Healthcare Solutions segment (now guided to 14-16% growth).
Increased to $480 million to $500 million (previously $315 million to $335 million). This rise is due to additional debt incurred to finance the OneOncology acquisition. Q2 interest expense is expected to be roughly double Q1 levels.
Hedging & Uncertainty: Management generally used precise language regarding financial targets, minimizing hedging when discussing the core business performance ('solidly within that long-term guidance range'). However, they employed hedging regarding the International segment's miss, labeling it a 'timing difference' and 'developing market country' issue to reassure investors it is non-recurring. They also used the phrase 'expect to be neutral' regarding OneOncology's EPS impact, which serves as a probabilistic hedge rather than a guarantee of immediate accretion.
We are confident our investments in MSOs will unlock new value creation opportunities... - James Cleary, Executive Vice President and CFO
We expect OneOncology to be neutral, net of financing costs, to adjusted diluted EPS in its first twelve months. - James Cleary, Executive Vice President and CFO
We're pausing share repo and focusing on deleveraging. - James Cleary, Executive Vice President and CFO
We have a very strong strategic global sourcing team and we were well prepared. - James Cleary, Executive Vice President and CFO
We're very pleased with the addition of RCA... both in terms of their performance and leadership. - Robert Mauch, President and CEO
We expect second quarter net interest expense to be about double our first quarter interest expense. - James Cleary, Executive Vice President and CFO
Analyst Sentiment: Analysts were inquisitive and focused on the mechanics of the OneOncology acquisition, specifically regarding accounting treatment, 'below the line' income, and the specific drivers of the raised guidance. There was skepticism regarding the deceleration of core US growth, leading to detailed questions about organic performance versus acquisition contributions.
Management Responses: Management was highly responsive and granular, providing specific breakdowns of financial impacts (e.g., the $30 million benefit from UUG joint venture). They effectively defended the core business performance by stripping out acquisition impacts to show underlying strength. They were transparent about the 'timing' issues in the International segment.
US Segment Core Growth: Analysts pressed for clarity on whether the core business was decelerating. Management clarified that excluding RCA and OneOncology, growth remains at the high end of the long-term 7-10% range.
OneOncology Accounting: Multiple questions focused on the non-controlling interests and 'below the line' income associated with OneOncology's UUG subsidiary. Management explained these items in detail to help analysts model the net income impact.
International Segment Weakness: Analysts asked for specifics on the operating income decline. Management attributed it to a one-time timing shift in manufacturer price adjustments in a developing market, maintaining full-year guidance.
MSO Synergies: Analysts inquired about the strategic rationale and immediate benefits of the MSO platform. Management highlighted cross-selling opportunities like clinical trials and revenue cycle management.
Cencora is successfully executing a strategic pivot from a traditional pharmaceutical distributor to a comprehensive healthcare solutions provider through its aggressive expansion into Management Services Organizations (MSOs). The acquisition of OneOncology, alongside Retina Consultants of America (RCA), creates a defensible moat in high-growth specialty markets (oncology and retina) by embedding Cencora deeply into the practice operations and patient care continuum. While the near-term financials face headwinds from rising interest expenses and the pause in share repurchases, the company raised its full-year guidance, demonstrating confidence in its ability to integrate these complex platforms and drive operating income growth of 11.5-13.5%. The core US distribution business remains resilient with solid utilization trends and GLP-1 growth, providing a stable cash flow engine to support the MSO expansion. Key success factors include the seamless integration of OneOncology to achieve the promised 'neutral to EPS' target in year one and the successful cross-pollination of capabilities (like clinical trials) across the MSO network. Risks involve the execution of debt reduction and the recovery of the International segment. Given the strategic positioning and raised guidance, the risk-reward remains attractive.
The transcript reveals sustained robust demand for GLP-1 drugs, with sales increasing by $1 billion (11%) in the quarter alone. This indicates that the obesity and diabetes treatment market continues to expand rapidly, benefiting distributors with high-volume flows. Furthermore, management's ability to maintain gross profit dollars despite IRA price negotiations suggests that the distributor supply chain retains essential leverage to negotiate with manufacturers, mitigating the impact of regulatory pricing pressure.
The success of Cencora's MSO strategy highlights a broader trend of physician practice consolidation and the need for operational scale. Independent community oncology and retina practices are increasingly partnering with large platforms to handle administrative burdens (revenue cycle, data analytics) and gain access to capital. This suggests a continued shift away from small, independent practices toward platform-based models in the US healthcare system.
The volatility in the International segment, specifically the 'timing of manufacturer price adjustments in a developing market country,' underscores the complexity and risk of operating in emerging pharmaceutical markets. It highlights how regulatory or pricing shifts in single developing nations can significantly impact multinational distributor earnings, suggesting a cautious outlook for emerging market exposure in the healthcare supply chain.